UA83620C2 - Замещенные бензоксазолы и их аналоги как эстрогенные агенты - Google Patents
Замещенные бензоксазолы и их аналоги как эстрогенные агентыInfo
- Publication number
- UA83620C2 UA83620C2 UA20040705301A UA20040705301A UA83620C2 UA 83620 C2 UA83620 C2 UA 83620C2 UA 20040705301 A UA20040705301 A UA 20040705301A UA 20040705301 A UA20040705301 A UA 20040705301A UA 83620 C2 UA83620 C2 UA 83620C2
- Authority
- UA
- Ukraine
- Prior art keywords
- analogues
- estrogenic agents
- substituted benzoxazoles
- benzoxazoles
- substituted
- Prior art date
Links
- 150000000183 1,3-benzoxazoles Chemical class 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33666301P | 2001-12-05 | 2001-12-05 | |
| PCT/US2002/038513 WO2003050095A1 (en) | 2001-12-05 | 2002-12-03 | Substituted benzoxazoles and analogues as estrogenic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83620C2 true UA83620C2 (ru) | 2008-08-11 |
Family
ID=23317104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705301A UA83620C2 (ru) | 2001-12-05 | 2002-03-12 | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6794403B2 (ru) |
| EP (2) | EP1982713A3 (ru) |
| JP (2) | JP4689960B2 (ru) |
| KR (1) | KR20050044717A (ru) |
| CN (2) | CN100443477C (ru) |
| AR (1) | AR037745A1 (ru) |
| AU (2) | AU2002353014A1 (ru) |
| BR (1) | BR0214767A (ru) |
| CA (1) | CA2467517C (ru) |
| CO (1) | CO5580830A2 (ru) |
| EC (1) | ECSP045133A (ru) |
| HU (1) | HUP0500010A2 (ru) |
| IL (1) | IL162256A0 (ru) |
| IN (1) | IN2005KO00272A (ru) |
| MX (1) | MXPA04005306A (ru) |
| NO (1) | NO20042811L (ru) |
| NZ (1) | NZ560878A (ru) |
| PL (1) | PL370771A1 (ru) |
| RU (2) | RU2330847C2 (ru) |
| SG (1) | SG165987A1 (ru) |
| TW (1) | TW200304822A (ru) |
| UA (1) | UA83620C2 (ru) |
| WO (1) | WO2003050095A1 (ru) |
| ZA (1) | ZA200405249B (ru) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229351B1 (en) | 2001-11-19 | 2013-11-28 | Lilly Co Eli | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| TW200409759A (en) | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
| EP1988397B8 (en) | 2002-12-19 | 2012-02-15 | The Scripps Research Institute | Compositions and uses for stabilising transthyretin and inhibiting transthyretin misfolding |
| PL1626974T3 (pl) * | 2003-04-21 | 2009-01-30 | Lilly Co Eli | Podstawione benzopirany jako selektywne związki agonistyczne receptora beta estrogenu |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| US20060004087A1 (en) * | 2004-07-01 | 2006-01-05 | Wyeth | Tetracyclic compounds as estrogen ligands |
| EP1781628A2 (en) * | 2004-08-26 | 2007-05-09 | Wyeth a Corporation of the State of Delaware | Prodrug substituted benzoxazoles as estrogenic agents |
| JP2008511666A (ja) | 2004-09-02 | 2008-04-17 | ワイス | サイトカインモジュレータとしてのフェナントリジンカルボニルフェノール |
| RU2007106870A (ru) | 2004-09-07 | 2008-10-20 | Вайет (Us) | 6Н-[1]БЕНЗОПИРАНО[4,3-b]ХИНОЛИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЭСТРОГЕННЫХ АГЕНТОВ |
| US20060121110A1 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| BRPI0518789A2 (pt) * | 2004-12-02 | 2008-12-09 | Wyeth Corp | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete |
| US20060121111A1 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| RU2007120254A (ru) * | 2004-12-17 | 2009-01-27 | Вайет (Us) | Новые способы применения агонистов эстрогена бета |
| US8093302B2 (en) * | 2005-02-15 | 2012-01-10 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-β agonists |
| KR20070103456A (ko) * | 2005-02-16 | 2007-10-23 | 와이어쓰 | 방사선- 또는 화학요법-유발 점막염 및 방사선 방광염용에스트로겐 수용체-β 선택적 아고니스트의 용도 |
| RU2007130408A (ru) | 2005-03-07 | 2009-04-20 | Вайет (Us) | Способ очистки замещенных соединений бензоксазола |
| AU2006220735A1 (en) * | 2005-03-07 | 2006-09-14 | Wyeth | Process for the preparation of substituted benzoxazole compounds |
| CN101137626A (zh) * | 2005-03-08 | 2008-03-05 | 惠氏公司 | 2－(3－氟－4－羟基苯基)－7－乙烯基－1,3－苯并唑－5－醇的晶形及其作为雌激素受体调节剂的用途 |
| US8940764B2 (en) | 2005-05-26 | 2015-01-27 | Aldexa Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| AU2007215131A1 (en) * | 2006-02-14 | 2007-08-23 | Wyeth | Aqueous pharmaceutical formulations of ERbeta selective ligands |
| PE20071019A1 (es) * | 2006-03-06 | 2007-10-29 | Wyeth Corp | Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos |
| AR059743A1 (es) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol |
| EP1993516A2 (en) * | 2006-03-06 | 2008-11-26 | Wyeth | Tablet formulations and processes |
| PE20080117A1 (es) * | 2006-03-06 | 2008-02-22 | Wyeth Corp | Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol |
| JP4986485B2 (ja) * | 2006-03-28 | 2012-07-25 | 株式会社Ａｄｅｋａ | エポキシ樹脂硬化性組成物 |
| WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
| US20090239920A1 (en) * | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080139633A1 (en) * | 2006-11-21 | 2008-06-12 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080176914A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080146630A1 (en) * | 2006-11-21 | 2008-06-19 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| WO2008064217A2 (en) * | 2006-11-21 | 2008-05-29 | Wyeth | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080132554A1 (en) * | 2006-11-21 | 2008-06-05 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| CN101641013B (zh) | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| JP2010516819A (ja) * | 2007-01-31 | 2010-05-20 | ワイス エルエルシー | 急性肺損傷を治療するためのＥＲβ選択的リガンドの使用 |
| WO2008100769A2 (en) * | 2007-02-09 | 2008-08-21 | Wyeth | Process for selective sulfation of aromatic hydroxyl groups |
| US20080262010A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts |
| US20080262008A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts |
| US20080275073A1 (en) * | 2007-04-20 | 2008-11-06 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts |
| US20080262009A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts |
| WO2009009417A2 (en) * | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| WO2009100335A1 (en) * | 2008-02-08 | 2009-08-13 | Wyeth | Phosphate derivatives of substituted benzoxazoles |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| BRPI0919816A2 (pt) * | 2008-09-26 | 2019-09-24 | Eisai R&D Man Co Ltd | uso compostos benzoxazólicos no tratamento de malária |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2011014516A1 (en) | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
| EP2621492A1 (en) * | 2010-10-01 | 2013-08-07 | Indiana University Research and Technology Corporation | Treatment of symptoms associated with menopause |
| US8865754B2 (en) * | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
| JP5869677B2 (ja) | 2011-09-16 | 2016-02-24 | ファイザー・インク | トランスサイレチン解離阻害剤の固体形態 |
| KR102062422B1 (ko) * | 2012-12-27 | 2020-01-03 | 수미토모 케미칼 컴퍼니 리미티드 | 융합된 옥사졸 화합물 및 그의 해충 방제를 위한 용도 |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| AU2014209585A1 (en) | 2013-01-25 | 2015-07-23 | Aldeyra Therapeutics, Inc. | Novel traps in the treatment of macular degeneration |
| EP3178810A4 (en) * | 2014-08-08 | 2018-07-04 | Kasuma Partners Inc. | Condensed heterocyclic compound |
| US10758496B2 (en) | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| CN104974103A (zh) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途 |
| CN104926745A (zh) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途 |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CA3054811A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| CN108586374B (zh) * | 2018-01-12 | 2021-01-05 | 浙江鼎龙科技有限公司 | 2-苯基苯并噁唑类化合物的制备方法 |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN111467341B (zh) * | 2020-04-24 | 2021-05-11 | 山东师范大学 | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 |
| CN114805112A (zh) * | 2022-05-31 | 2022-07-29 | 常州大学 | 一种pde2抑制剂酰胺类衍生物及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435721A (en) * | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| GB1590587A (en) | 1977-06-28 | 1981-06-03 | Lilly Industries Ltd | Benoxaprofen |
| ZA953311B (en) * | 1994-04-29 | 1996-10-24 | Lilly Co Eli | Non-peptidyl tachykinin receptor antagonists |
| ATE183516T1 (de) | 1995-09-08 | 1999-09-15 | Karobio Ab | Waisen-rezeptor |
| US5919808A (en) * | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US5948776A (en) * | 1996-10-23 | 1999-09-07 | Zymogenetic, Inc. | Compositions and methods for treating bone deficit conditions |
| US7157568B1 (en) | 1997-08-05 | 2007-01-02 | American Home Products Corporation | Human estrogen receptor-β |
| EE04641B1 (et) | 1998-05-05 | 2006-06-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Bensimidasoolid ja bensoksasoolid, nende kasutamine hingamisteede ja dermatooside raviks ette nähtud ravimite valmistamiseks ning neid sisaldav ravim |
| ATE263166T1 (de) | 1998-07-06 | 2004-04-15 | Altana Pharma Ag | Neue benzoxazole mit pde-hemmender wirkung |
| GB9814620D0 (en) | 1998-07-06 | 1998-09-02 | Karobio Ab | Vasculoprotector |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| WO2000031112A1 (en) | 1998-11-20 | 2000-06-02 | Akzo Nobel N.V. | Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 |
| US6331562B1 (en) * | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU765159B2 (en) | 1998-12-30 | 2003-09-11 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6358943B1 (en) * | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
| CA2367895A1 (en) * | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU3964400A (en) | 1999-04-06 | 2000-10-23 | Akzo Nobel N.V. | Selective estrogenic compounds |
| ES2211540T3 (es) | 1999-04-09 | 2004-07-16 | Karo Bio Ab | Receptores de estrogenos y hueso. |
| CA2370126A1 (en) * | 1999-04-16 | 2000-10-26 | Timothy Martin Piser | Estrogen receptor-.beta. ligands |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| GB9913649D0 (en) | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| EP1257264B1 (en) | 2000-02-14 | 2011-09-14 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US6559177B2 (en) * | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| EP1781628A2 (en) * | 2004-08-26 | 2007-05-09 | Wyeth a Corporation of the State of Delaware | Prodrug substituted benzoxazoles as estrogenic agents |
-
2002
- 2002-03-12 UA UA20040705301A patent/UA83620C2/ru unknown
- 2002-12-03 CN CNB028278186A patent/CN100443477C/zh not_active Expired - Fee Related
- 2002-12-03 NZ NZ560878A patent/NZ560878A/en unknown
- 2002-12-03 TW TW091135030A patent/TW200304822A/zh unknown
- 2002-12-03 HU HU0500010A patent/HUP0500010A2/hu unknown
- 2002-12-03 CN CNA2008101731403A patent/CN101423500A/zh active Pending
- 2002-12-03 RU RU2004120283/04A patent/RU2330847C2/ru active
- 2002-12-03 PL PL02370771A patent/PL370771A1/xx unknown
- 2002-12-03 JP JP2003551120A patent/JP4689960B2/ja not_active Expired - Fee Related
- 2002-12-03 SG SG200603829-3A patent/SG165987A1/en unknown
- 2002-12-03 BR BR0214767-0A patent/BR0214767A/pt not_active IP Right Cessation
- 2002-12-03 WO PCT/US2002/038513 patent/WO2003050095A1/en active Application Filing
- 2002-12-03 AU AU2002353014A patent/AU2002353014A1/en not_active Abandoned
- 2002-12-03 CA CA2467517A patent/CA2467517C/en not_active Expired - Fee Related
- 2002-12-03 KR KR1020047008680A patent/KR20050044717A/ko active IP Right Grant
- 2002-12-03 EP EP07023848A patent/EP1982713A3/en not_active Withdrawn
- 2002-12-03 IL IL16225602A patent/IL162256A0/xx unknown
- 2002-12-03 EP EP02789980A patent/EP1451165A1/en not_active Withdrawn
- 2002-12-03 MX MXPA04005306A patent/MXPA04005306A/es active IP Right Grant
- 2002-12-04 AR ARP020104690A patent/AR037745A1/es unknown
- 2002-12-04 US US10/309,699 patent/US6794403B2/en not_active Expired - Fee Related
-
2004
- 2004-05-17 US US10/847,100 patent/US7148247B2/en not_active Expired - Fee Related
- 2004-06-01 CO CO04050963A patent/CO5580830A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005133A patent/ECSP045133A/es unknown
- 2004-07-01 ZA ZA200405249A patent/ZA200405249B/en unknown
- 2004-07-02 NO NO20042811A patent/NO20042811L/no not_active Application Discontinuation
- 2004-08-19 US US10/921,409 patent/US7129258B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 IN IN272KO2005 patent/IN2005KO00272A/en unknown
-
2006
- 2006-12-11 US US11/636,947 patent/US7531564B2/en not_active Expired - Fee Related
-
2008
- 2008-02-26 RU RU2008107295/04A patent/RU2008107295A/ru not_active Application Discontinuation
-
2009
- 2009-08-17 AU AU2009210357A patent/AU2009210357A1/en not_active Ceased
-
2010
- 2010-11-15 JP JP2010255175A patent/JP2011052010A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83620C2 (ru) | Замещенные бензоксазолы и их аналоги как эстрогенные агенты | |
| MXPA05012249A (es) | Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos. | |
| WO2003051805A3 (en) | Substituted phenyl naphthalenes as estrogenic agents | |
| MXPA06001592A (es) | Derivados de (4-hidroxifenil)-1h-indol-3-carbaldehido oxima como agentes estrogenicos. | |
| MXPA04005784A (es) | 2-fenilbenzofuranos sustituidos como agentes estrogenitos. | |
| MXPA05011679A (es) | Derivados de hidroxibifenilcarbaldehido oxima y su uso como agentes estrogenicos. | |
| TW200612925A (en) | Prodrug substituted benzoxazoles as estrogenic agents | |
| MXPA04004674A (es) | Ligados de los receptors de los canabinodies. | |
| IL155236A0 (en) | Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity | |
| TW200510319A (en) | Phenyl quinolines and their use as estrogenic agents | |
| MXPA02012891A (es) | Composiciones farmaceuticas de agentes estrogenicos. | |
| HK1071059A1 (en) | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis | |
| DE60216233D1 (en) | Carbolinderivate | |
| MXPA03002911A (es) | Compuestos quimicos. | |
| EP1417153A4 (en) | N, N-DINITRAMIDE SALTS AS SOLUBILIZATION AGENTS FOR BIOLOGICALLY ACTIVE AGENTS | |
| AP2002002616A0 (en) | Antidibetic agents | |
| HK1045990A1 (en) | Novel derivatives and analogues of galanthamin. | |
| AU1366802A (en) | 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | |
| AU2003227595A1 (en) | Foam control agents | |
| TWI255813B (en) | Compounds for use as alphavbeta3 receptor antagonists | |
| AU3476599A (en) | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists) | |
| DK1652526T3 (da) | Anvendelse af (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-on i behandling af svær depressionslidelse | |
| WO2000007544A3 (en) | Vitronectin receptor antagonists | |
| AU2002322433A1 (en) | N,n-dinitramide salts as solubilizing agents for biologically active agents | |
| TW200740442A (en) | Therapeutic agent for hypertension |